fashion -WSS

fashion

author：fashion 2025-10-02 23:31:29 - browse：46

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： How the drug

WSS

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Trans patients at the end of life deserve respect and dignity

Will the FTC rein in IQVIA's health data empire?

What to watch for from Zogenix and Amicus clinical trials

Former reverend arrested for allegedly killing 8

CDC Director Mandy Cohen on transparency, trust, and health

entertainment

fashion

knowledge

Medicare details structure of new drug price negotiation program

PBMs are inflating the cost of generic drugs. They must be reined in

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Continuity nursing helped my family in our darkest PICU moments

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Sports medicine is finally prioritizing gender equality

What to watch for from Zogenix and Amicus clinical trials

In age of alternative facts, a scholarly course on calling out crap

Study: Spinal cord stimulation helps patients with paralysis walk again

focus

What it's like to live with paralysis for one psychologist

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Roche's accidental data boosts hopes for anti

UHS says company favors patients whose insurance pays more

How the first Native Hawaiian psychiatrist helped diversify medicine

New Alzheimer's drugs heat up race for early detection blood tests

hotspot

hotspot

entertainment

leisure time